Attached files

file filename
EX-99.2 - EXHIBIT 99.2 - Lexaria Bioscience Corp.exhibit99-2.htm
EX-99.1 - EXHIBIT 99.1 - Lexaria Bioscience Corp.exhibit99-1.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) October 26, 2016

LEXARIA BIOSCIENCE CORP.
(Exact name of registrant as specified in its charter)

Nevada 000-52138 20-2000871
(State or other jurisdiction of (Commission File Number) (IRS Employer
incorporation)   Identification No.)

156 Valleyview Road, Kelowna, BC Canada V1X 3M4
(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code (250) 765-2111

LEXARIA CORP.
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[   ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[   ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
[   ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
[   ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Item 3.02          Unregistered Sales of Equity Securities

On October 27, 2016, Lexaria announced that it has settled an existing US$9,000 debt with a former executive consultant of the firm by issuing 56,250 restricted common shares at an issuance price of US$0.16 per share, as payment in full for the obligation.

The securities referred to herein will not be or have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Item 7.01          Regulation FD Disclosure

A copy of the news releases dated October 26 and 27, 2016 announcing the issuance of a U.S. Patent and an early exercise incentive for warrant holders are attached as Exhibits 99.1 and 99.2 to this current report and are hereby incorporated by reference.


- 2 -

Item 9.01         Financial Statements and Exhibits

99.1

Press Release dated October 26, 2016

   
99.2

Press Release dated October 27, 2016

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LEXARIA BIOSCIENCE CORP.

 

/s/ Chris Bunka  
Chris Bunka  
CEO, Principal Executive Officer  
   
Date:     October 28, 2016